Ezetimibe polymorphs
    47.
    发明申请
    Ezetimibe polymorphs 审中-公开
    依泽替米贝多晶型物

    公开(公告)号:US20060160785A1

    公开(公告)日:2006-07-20

    申请号:US11295141

    申请日:2005-12-05

    IPC分类号: A61K31/397 C07D205/02

    CPC分类号: C07D205/08

    摘要: Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe Form A, micronized ezetimibe Form B, and ezetimibe having a plate morphology. Pharmaceutical compositions containing these forms are particularly useful in reducing cholesterol in patients in need thereof.

    摘要翻译: 提供了制备依泽替米贝的结晶形式的方法,例如依泽替米贝形式A或B型,例如通过从选择的溶剂中沉淀依泽替米贝。 或者,一些形式可以在升高的温度或在各种湿度条件下或通过微粉化转化成不同的形式。 还提供了微粒化的依泽替米贝形式A,微粉化的依泽替米贝形式B和具有平板形态的依泽替米贝。 含有这些形式的药物组合物特别可用于降低有需要的患者的胆固醇。

    Crystalline form IV of linezolid
    48.
    发明申请
    Crystalline form IV of linezolid 审中-公开
    利奈唑胺的结晶形式IV

    公开(公告)号:US20060142283A1

    公开(公告)日:2006-06-29

    申请号:US11171098

    申请日:2005-06-29

    IPC分类号: A61K31/535

    CPC分类号: A61K31/535 C07D263/20

    摘要: The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering from gram-positive bacterial infections. Various processes for making crystalline linezolid Form IV are disclosed.

    摘要翻译: 本发明提供了本文称为形式IV的利奈唑胺的新型结晶形式以及制备和使用形式IV的方法。 本发明提供包含治疗有效量的形式IV的药物组合物,其可用于治疗患有革兰氏阳性细菌感染的患者。 公开了制备结晶利奈唑胺形式IV的各种方法。

    Solid forms of linezolid and processes for preparation thereof
    49.
    发明申请
    Solid forms of linezolid and processes for preparation thereof 审中-公开
    固体形式的利奈唑胺及其制备方法

    公开(公告)号:US20060111350A1

    公开(公告)日:2006-05-25

    申请号:US11171579

    申请日:2005-06-29

    IPC分类号: A61K31/5377 C07D413/02

    CPC分类号: C07D263/20

    摘要: Novel crystalline forms of Linezolid, designated as Form TIII, Form V, Form VI, Form IX, Form X, Form XII, Form XIV, Form XVII, and Form XVIII, are disclosed. The novel crystalline forms are characterized by powder X-ray diffraction, FTIR and FTRaman spectroscopy, and differential scanning calorimetry. Methods of preparing the novel crystalline forms, pharmaceutical compositions comprising the novel crystalline forms, and methods of using the novel crystalline forms to treat gram positive bacterial infections are also described. Amorphous Linezolid is also disclosed.

    摘要翻译: 公开了新型晶体形式的利奈唑胺,称为形式TIII,形式V,形式VI,形式IX,形式X,形式XII,形式XIV,形式XVII和形式XVIII。 新型结晶形式的特征在于粉末X射线衍射,FTIR和FTRaman光谱学以及差示扫描量热法。 还描述了制备新结晶形式的方法,包含新结晶形式的药物组合物,以及使用新型结晶形式治疗革兰氏阳性细菌感染的方法。 还公开了无定形利奈唑胺。